Company intelligence / Profile preview

TME Pharma

Ownership: Private
Employees: ~20
Development stage: Other

Overview

TME Pharma’s lead compound, NOX-A12, in combination with radiotherapy and anti‑VEGF therapy in glioblastoma has shown statistically significant improvement in survival compared to historical controls, including a doubling of median overall survival. The company has also reported encouraging safety and efficacy data from its pancreatic cancer trial combining NOX-A12 with immunotherapy. Both programs are ready for further development pending additional financing or partnerships

Therapeutic areas: OphthalmologyHematologyEndocrinologyOncology
Modalities: RNA therapyAptamer
Industry: Biotech

Drug pipeline

6 assets

olaptesed pegol

5 more assets in the full pipeline.

Partnerships

Merck/MSD – collaboration on pancreatic cancer trial using Keytruda®Singapore Eye Research Institute – ophthalmology option framework agreement for NOX-E36

Beyond the preview

Go deeper on TME Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TME Pharma.